Download e-book for kindle: Anthracycline Chemistry and Biology II: Mode of Action, by Giovanni Luca Beretta, Franco Zunino (auth.), Karsten Krohn

By Giovanni Luca Beretta, Franco Zunino (auth.), Karsten Krohn (eds.)

ISBN-10: 3540758127

ISBN-13: 9783540758129

see desk of contents

Show description

Read Online or Download Anthracycline Chemistry and Biology II: Mode of Action, Clinical Aspects and New Drugs PDF

Similar chemistry books

Download PDF by Linus Pauling: How to Live Longer and Feel Better

How one can reside Longer and consider greater attracts on two-time Nobel prize winner Linus Pauling's enormous medical wisdom and many good judgment. the result's a remarkably functional plan for including years on your existence.

Thilo J. Heckrodt, Johann Mulzer (auth.), Johann Mulzer's Natural Products Synthesis II: Targets, Methods, Concepts PDF

T. J. Heckrodt and J. H. Mulzer: Marine typical items from Pseudopterogorgia Elisabethae: buildings, Biosynthesis, Pharmacology and overall Synthesis . - M. Kalesse: Vinylogous Aldol Reactions and their functions within the Syntheses of ordinary items . -U. Beifuss and M. Tietze: Methanophenazine and different typical Biologically energetic Phenazines .

Extra info for Anthracycline Chemistry and Biology II: Mode of Action, Clinical Aspects and New Drugs

Example text

Noncardiotoxic Anthracycline Analogs . Modulators of Anthracycline Degradation . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 Cardiotoxic Synergism of Anthracyclines with Other Drugs . . . . Anthracyclines and Taxanes . . . . . . . . . . . . . Anthracyclines and Trastuzumab . . . . . . . . . . . . 36 36 38 References . . . . . . . . . . . . . . . . . . . . 41 . . . . . . . . . . . . . . . . .

22 2 Pharmacokinetic Determinants of Cardiotoxicity . . . . . . . 3 Metabolic Determinants of Cardiotoxicity . . . . One-Electron Reductive Bioactivation . . . . . Two-Electron Reductive Bioactivation . . . . . One-Electron Oxidative Degradation and Detoxification . . . . . . . . . . . . . . . . . . . . . . 4 Translating the Metabolic Determinants of Cardiotoxicity into Protective Strategies Antioxidants . . . . . . . .

Myocet® was also probed in metastatic breast cancer patients who had received DOX in the adjuvant setting. Also in these patients Myocet® showed a good activity vis-à-vis a limited cardiotoxicity, a finding that conceptually re-opened the door to the use of DOX in patients with a previous exposure to anthracyclines [13]. Caelyx® was designed to escape degradation by cells of the reticuloendothelial system and hence, to generate a blood circulation time and an intratumoral drug-liposomal deposition even higher than those obtained with Myocet®.

Download PDF sample

Anthracycline Chemistry and Biology II: Mode of Action, Clinical Aspects and New Drugs by Giovanni Luca Beretta, Franco Zunino (auth.), Karsten Krohn (eds.)


by Michael
4.0

Rated 4.35 of 5 – based on 29 votes